Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates—proof of concept for HIV mucosal pre-exposure prophylaxis

Abstract

Local delivery of anti-HIV drugs to the colorectal mucosa, a major site of HIV replication, and their retention within mucosal tissue would allow for a reduction in dose administered, reduced dosing frequency and minimal systemic exposure. The current report describes a mucosal Pre-Exposure Prophylaxis (mPrEP) strategy that utilizes nanocarrier conjugates (NC) consisting of poly(ethylene glycol) (PEG), amprenavir (APV) and a cell penetrating peptide (CPP; namely Bac7, a fragment derived from bactenecin 7). APV-PEG NCs with linear PEGs (2, 5, 10, and 30 kDa) exhibited reduced (52 – 21%) anti-HIV-1 protease (PR) activity as compared to free APV in an enzyme-based FRET assay. In MT-2 T-cells, APV-PEG3.4kDa-FITC (APF) anti-HIV-1 activity was significantly reduced (160-fold, IC50 = 8.064 µM) due to poor cell uptake whereas it was restored (IC50 = 78.29 nM) and similar to APV (IC50 = 50.29 nM) with the addition of Bac7 to the NC (i.e., APV-PEG3.4kDa-Bac7, APB). Flow cytometry and confocal microscopy demonstrated Bac7-PEG3.4kDa-FITC (BPF) uptake was two- and four-fold higher than APF in MT-2 T-cells and Caco-2 intestinal epithelial cells, respectively. There was no detectable punctate fluorescence in either cell line suggesting that BPF directly enters the cytosol thus avoiding endosomal entrapment. After colorectal administration in mice, BPF mucosal concentrations were 21-fold higher than APF concentrations. BPF concentrations also remained constant for the 5 days of the study suggesting that (1) the NC’s structural characteristics (i.e., the size of the PEG carrier and the presence of a CPP) significantly influenced tissue persistence and (2) the NCs were probably lodged in the lamina propria since the average rodent colon mucosal cell turnover time is 2–3 days. These encouraging results suggest that Bac7 functionalized NCs delivered locally to the colorectal mucosa may form drug delivery depots that are capable of sustaining colorectal drug concentrations. Although the exact mechanisms for tissue persistence are unclear and will require further study, these results provide proof-of-concept feasibility for mPrEP.

Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems

“…Thus, for the purpose of this work, all nanosuspensions are considered as de facto dosage forms. Saline-based buffers (approximately isoosmolal and with the pH around neutral) have been the most commonly used vehicles [52,53,80,81]. Indeed, particular attention should be given to pH and osmolality, as these factors are recognized to potentially affect safety [82].…”

Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies

“…Dissolving microneedles can be formulated from inert material such as polymers and sugars including trehalose, sucrose, arginine and hepatagluconate in which vaccine is encapsulated into the tip of the needle. These materials allow more effective delivery upon patch application, increase the stability of the vaccine and are approved for human use [ 101 , 102 ]. The microneedles dissolve in the skin, releasing the vaccine and eliminating the need for sharps or biohazardous waste disposal [ 102 ].…”

Development of peptide inhibitors of HIV transmission

“…High dosage is needed for current anti-gp120 antibodies [173] . Due to such limitations, microbicides were used as an alternative to oral administration or injection for several promising peptide entry inhibitors (T20 (Enfuvirtide) [174] , T1249 [175] , L′644 [176] and Sifuvirtide [177] ).…”